Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 27.
doi: 10.1097/PAS.0000000000002465. Online ahead of print.

Postneoadjuvant Whipple Resections Show Significant Residual Microscopic Tumor Beyond Grossly Identified Tumor Bed: Implications for Accurate Tumor Staging

Komson Wannasai  1   2 , Anthony R Russo  1   3 , Stuti G Shroff  1   3 , Jonathan N Glickman  1   3 , Anthony Mattia  1   3 , M Lisa Zhang  1   3 , Maria L Ganci  1 , Anna Rider  1 , Fernandez-Del Castillo Carlos  4   3 , Mari Mino-Kenudson  1   3 , Angela R Shih  1   3
Affiliations

Postneoadjuvant Whipple Resections Show Significant Residual Microscopic Tumor Beyond Grossly Identified Tumor Bed: Implications for Accurate Tumor Staging

Komson Wannasai et al. Am J Surg Pathol. .

Abstract

Neoadjuvant chemotherapy plays a vital role in the treatment of pancreatic ductal adenocarcinoma (PDAC), but treatment effect complicates pathologic examination of postneoadjuvant Whipple resections. Institutional practice is variable but current Pancreatobiliary Pathology Society (PBPS) guidelines suggest extensive microscopic examination of the tumor bed (TB). In practice, gross identification of TB is challenging and may lead to an inaccurate assessment of tumor size. The purpose of this study is to evaluate the adequacy of current practice in postneoadjuvant Whipple resections for pathologic staging. A single institutional prospective cohort was assessed, including 29 entirely submitted (ES) specimens and 10 current PBPS guideline-based (CG) specimens. Cases were evaluated for TB gross measurement, TB microscopic tumor, nontumor bed (N-TB) microscopic tumor, overall size assessment by microscopic evaluation, and presence of lymph nodes with metastases. ES and CG specimens showed similar overall residual tumor size measurements under the current PBPS guidelines protocol, but with the entire submission, tumor size increased by an average of 0.5 cm (range: 0.0 to 2.1 cm). Twenty-eight percent had an upstaged ypT due to a significant N-TB tumor. These findings delineate the limitations of gross TB assessment in postneoadjuvant Whipple resections for adequate pathologic staging and appropriate prognostication.

Keywords: neoadjuvant therapy; neoplasm staging; pancreatic neoplasms; residual neoplasm.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

References

    1. Huang J, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterol. 2021;160:744–754.6
    1. Bethesda NCInstitute, MD SEER Cancer Stat Facts: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html
    1. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210.
    1. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481.
    1. Petrelli F, Coinu A, Borgonovo K, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer. Pancreas. 2015;44:515–521.

LinkOut - more resources